FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081830235> ?p ?o ?g. }

• W3081830235 endingPage "1424" @default.
• W3081830235 startingPage "1413" @default.
• W3081830235 abstract "Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction.In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure.During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001). The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28 ml per minute per 1.73 m2 of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin.Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Reduced ClinicalTrials.gov number, NCT03057977.)." @default.
• W3081830235 created "2020-09-08" @default.
• W3081830235 creator A5003943960 @default.
• W3081830235 creator A5005631453 @default.
• W3081830235 creator A5006125844 @default.
• W3081830235 creator A5008678419 @default.
• W3081830235 creator A5016763799 @default.
• W3081830235 creator A5022314919 @default.
• W3081830235 creator A5023320363 @default.
• W3081830235 creator A5023436129 @default.
• W3081830235 creator A5025046655 @default.
• W3081830235 creator A5027821454 @default.
• W3081830235 creator A5033368647 @default.
• W3081830235 creator A5034399975 @default.
• W3081830235 creator A5036821495 @default.
• W3081830235 creator A5039697719 @default.
• W3081830235 creator A5042766753 @default.
• W3081830235 creator A5043021945 @default.
• W3081830235 creator A5043064522 @default.
• W3081830235 creator A5043416120 @default.
• W3081830235 creator A5043576007 @default.
• W3081830235 creator A5047234903 @default.
• W3081830235 creator A5055849986 @default.
• W3081830235 creator A5057090750 @default.
• W3081830235 creator A5057386346 @default.
• W3081830235 creator A5057857029 @default.
• W3081830235 creator A5057864298 @default.
• W3081830235 creator A5060241741 @default.
• W3081830235 creator A5061687360 @default.
• W3081830235 creator A5066275468 @default.
• W3081830235 creator A5071539782 @default.
• W3081830235 creator A5072059904 @default.
• W3081830235 creator A5074299303 @default.
• W3081830235 creator A5074947929 @default.
• W3081830235 creator A5075319533 @default.
• W3081830235 creator A5075925255 @default.
• W3081830235 creator A5075949562 @default.
• W3081830235 creator A5078498803 @default.
• W3081830235 creator A5080334509 @default.
• W3081830235 creator A5086692319 @default.
• W3081830235 creator A5091849037 @default.
• W3081830235 date "2020-10-08" @default.
• W3081830235 modified "2023-10-18" @default.
• W3081830235 title "Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure" @default.
• W3081830235 cites W2626446274 @default.
• W3081830235 cites W2899764361 @default.
• W3081830235 cites W2903431537 @default.
• W3081830235 cites W2913306188 @default.
• W3081830235 cites W2919368874 @default.
• W3081830235 cites W2921866736 @default.
• W3081830235 cites W2958440246 @default.
• W3081830235 cites W2974260792 @default.
• W3081830235 cites W3008610985 @default.
• W3081830235 cites W3012101497 @default.
• W3081830235 doi "https://doi.org/10.1056/nejmoa2022190" @default.
• W3081830235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32865377" @default.
• W3081830235 hasPublicationYear "2020" @default.
• W3081830235 type Work @default.
• W3081830235 sameAs 3081830235 @default.
• W3081830235 citedByCount "2446" @default.
• W3081830235 countsByYear W30818302352018 @default.
• W3081830235 countsByYear W30818302352019 @default.
• W3081830235 countsByYear W30818302352020 @default.
• W3081830235 countsByYear W30818302352021 @default.
• W3081830235 countsByYear W30818302352022 @default.
• W3081830235 countsByYear W30818302352023 @default.
• W3081830235 crossrefType "journal-article" @default.
• W3081830235 hasAuthorship W3081830235A5003943960 @default.
• W3081830235 hasAuthorship W3081830235A5005631453 @default.
• W3081830235 hasAuthorship W3081830235A5006125844 @default.
• W3081830235 hasAuthorship W3081830235A5008678419 @default.
• W3081830235 hasAuthorship W3081830235A5016763799 @default.
• W3081830235 hasAuthorship W3081830235A5022314919 @default.
• W3081830235 hasAuthorship W3081830235A5023320363 @default.
• W3081830235 hasAuthorship W3081830235A5023436129 @default.
• W3081830235 hasAuthorship W3081830235A5025046655 @default.
• W3081830235 hasAuthorship W3081830235A5027821454 @default.
• W3081830235 hasAuthorship W3081830235A5033368647 @default.
• W3081830235 hasAuthorship W3081830235A5034399975 @default.
• W3081830235 hasAuthorship W3081830235A5036821495 @default.
• W3081830235 hasAuthorship W3081830235A5039697719 @default.
• W3081830235 hasAuthorship W3081830235A5042766753 @default.
• W3081830235 hasAuthorship W3081830235A5043021945 @default.
• W3081830235 hasAuthorship W3081830235A5043064522 @default.
• W3081830235 hasAuthorship W3081830235A5043416120 @default.
• W3081830235 hasAuthorship W3081830235A5043576007 @default.
• W3081830235 hasAuthorship W3081830235A5047234903 @default.
• W3081830235 hasAuthorship W3081830235A5055849986 @default.
• W3081830235 hasAuthorship W3081830235A5057090750 @default.
• W3081830235 hasAuthorship W3081830235A5057386346 @default.
• W3081830235 hasAuthorship W3081830235A5057857029 @default.
• W3081830235 hasAuthorship W3081830235A5057864298 @default.
• W3081830235 hasAuthorship W3081830235A5060241741 @default.
• W3081830235 hasAuthorship W3081830235A5061687360 @default.
• W3081830235 hasAuthorship W3081830235A5066275468 @default.
• W3081830235 hasAuthorship W3081830235A5071539782 @default.
• W3081830235 hasAuthorship W3081830235A5072059904 @default.
• W3081830235 hasAuthorship W3081830235A5074299303 @default.

• next